AZD0233
AZD0233 is an orally active CX3CR1 antagonist. AZD0233 modulates the CX3CR1/CX3CL1 signaling axis via immunomodulatory effects. AZD0233 has improved physicochemical properties, metabolic stability, low toxicity and CYP inhibition. AZD0233 improves cardiac function and reduces macrophages and fibrotic scar in mice model of dilated cardiomyopathy. AZD0233 can be used for cardiovascular diseases like dilated cardiomyopathy research[1].
Product Specifications
CAS Number
3036141-78-0
UNSPSC
12352005
Target
CX3CR1
Related Pathways
Immunology/Inflammation
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Purity
98.66
Solubility
DMSO : 5 mg/mL (ultrasonic)
Smiles
COC1=CC(F)=C(C=N1)[C@@H](CC2=NC(NS(C)(=O)=O)=NC(N[C@H](CC(C)C)CO)=N2)C
Molecular Formula
C19H29FN6O4S
Molecular Weight
456.53
References & Citations
[1]Karolina N, et al. AZD0233: An oral CX3CR1 antagonist in development for the treatment of cardiovascular disease. ACS. 2025 Aug 20.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Hapten 4-hydroxy-3-nitrophenyl Acetyl NP discontinued